EWTX
Edgewise Therapeutics, Inc.About EWTX
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
Company
- Headquarters
- Boulder, CO
- Employees
- 127 (2026)
- Listed
- Mar 26, 2021
- Exchange
- Nasdaq
- Website
- edgewisetx.com
- SEC industry
- Pharmaceutical Preparations
- Cylvex sector
- Health Care · Pharmaceuticals
Pharmaceuticals
- Market cap #55 of 430
- P/B #48 of 396
Ranked highest first among stocks Cylvex covers.
- LLYEli Lilly and Company$1.26T+0.60%
- JNJJohnson & Johnson$665.3B+3.83%
- ABBVAbbVie Inc$520.9B+3.07%
- MRKMerck & Co Inc$370.9B+3.91%
- NVSNovartis AG$311.6B+3.60%
Financial summary
Related companies
About
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
From company filings and market data · Not investment advice
Price data
From daily bars
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.